GLP-1
Novo Nordisk specializes in the diabetes market. The company appears to be making an entry into the Alzheimer’s market, which isn’t as unusual or unexpected as it initially sounds.
For patients with diabetes, the new indication could become a key for survival as there is a well-established link between cardiovascular disease and type 2 diabetes.
NBE-Therapeutics AG announces the closing of a USD 22M Series C financing round, led by its existing shareholders Boehringer Ingelheim Venture Fund and the PPF Group and with participation from all private shareholders.
Antabio’s Pseudomonas Elastase Inhibitor (PEi) has the potential to significantly enhance the effectiveness of current CF therapy
With a new year upon us, some analysts are already picking potential winners in the market for 2020. One of those companies could be Denmark-based Novo Nordisk.
Looking back over the past year and even decade, STAT News takes a look back at the best drugs approved over the past 10 years in its weekly Readout podcast.
Adocia, a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of approved proteins, announced its financial calendar for 2020.
Companies from across the globe provide updates on their business and product pipelines.
Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without any modifications, based on the pre-planned review of safety data
Galapagos NV announces a share capital increase arising from warrant exercises.
PRESS RELEASES